In its investor call on Thursday, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta.
In its investor call on Thursday, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta. The drug’s launch is slated for January 3, 2019. Udenyca’s list price of $4175 per unit matches Mylan’s price for its biosimilar pegfilgrastim, Fulphila, which launched in the United States in July 2018.
Prior to Coherus’ announcement of its price for its product, Mylan was the only the second biosimilar developer to offer a discount deeper than 30% in the US market; Samsung Bioepis’ infliximab biosimilar, Renflexis, launched at a 35% discount to its reference, but other products, such as Celltrion’s Inflectra and Sandoz’s Zarxio, launched at discounts of just 15%.
Despite the fact that Coherus has matched Mylan on list price for the pegfilgrastim product, these prices do not take into consideration additional rebates and discounts that the drug makers may offer as a means to differentiate their products in the marketplace.
Coherus also noted in its investor call that it has finished hiring approximately 70 sales representatives, covering 7 US regions, to support sales of Udenyca. The company also recently launched a comprehensive website for its provider services, reimbursement support, and patient co-pay assistance program.
Looking to the future, Coherus reported that it plans to file a Biologics License Application for its adalimumab biosimilar referencing Humira, CHS-1420, before the end of 2019. It is also working on 2 biosimilars targeting eye diseases: CHS-3351 (a ranibizumab biosimilar referencing Lucentis) and CHS-2020 (an aflibercept biosimilar referencing Eylea).
Notably, the company, which has thus far focused on biosimilars, also reports that it plans to initiate a phase 2 clinical trial of an innovator small-molecule drug. CHS-131 is a candidate drug for the treatment of nonalcoholic steatohepatitis, or NASH.
The diversification into innovator drug development has also been the strategy of other biosimilar developers in recent months; Samsung Bioepis has announced that it is in a phase 1 clinical trial with SB26, an novel ulinastatin-Fc fusion protein, and Celltrion has expanded its pipeline to include innovator biologics for the treatment breast cancer, hepatitis B virus, and rabies.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Top 5 Most-Read Oncology Articles of 2024
December 24th 2024The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.